Illustration: Assistant editor Kathy Wong for Endpoints News
In the early days of the Covid-19 pandemic, when many trials were grounded, Jason Luke and his fellow clinical researchers at the University of Pittsburgh Medical Center were still testing new cancer drugs in 50 Phase I studies. Now, his colleagues only have the bandwidth to handle one-fifth the amount of early-stage trials as they did in early 2021.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
